Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Meloxicam
  • 1.4.3 Celecoxib
  • 1.4.4 Etoricoxib
  • 1.4.5 Imrecoxib
  • 1.4.6 Etodolac
  • 1.4.7 Parecoxib
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application (2014-2025)
  • 1.5.2 Rheumatoid Arthritis
  • 1.5.3 Osteoarthritis
  • 1.5.4 Spondylosis Chronica Ankylopoietica
  • 1.5.5 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Selective Cox-2 Inhibitors Market Size
• 2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
  • 2.2.1 Selective Cox-2 Inhibitors Market Size by Regions (2014-2025)
  • 2.2.2 Selective Cox-2 Inhibitors Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Selective Cox-2 Inhibitors Market Size by by Players
  • 3.1.1 Global Selective Cox-2 Inhibitors Revenue by by Players (2014-2019)
  • 3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
• 3.2 Selective Cox-2 Inhibitors Key Players Head office and Area Served
• 3.3 Key Players Selective Cox-2 Inhibitors Product/Solution/Service
• 3.4 Date of Enter into Selective Cox-2 Inhibitors Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Selective Cox-2 Inhibitors Market Size by Type (2014-2019)
• 4.2 Global Selective Cox-2 Inhibitors Market Size by Application (2014-2019)

5 United States

• 5.1 United States Selective Cox-2 Inhibitors Market Size (2014-2019)
• 5.2 Selective Cox-2 Inhibitors Key Players in United States
• 5.3 United States Selective Cox-2 Inhibitors Market Size by Type
• 5.4 United States Selective Cox-2 Inhibitors Market Size by Application

6 Europe

• 6.1 Europe Selective Cox-2 Inhibitors Market Size (2014-2019)
• 6.2 Selective Cox-2 Inhibitors Key Players in Europe
• 6.3 Europe Selective Cox-2 Inhibitors Market Size by Type
• 6.4 Europe Selective Cox-2 Inhibitors Market Size by Application

7 China

• 7.1 China Selective Cox-2 Inhibitors Market Size (2014-2019)
• 7.2 Selective Cox-2 Inhibitors Key Players in China
• 7.3 China Selective Cox-2 Inhibitors Market Size by Type
• 7.4 China Selective Cox-2 Inhibitors Market Size by Application

8 Japan

• 8.1 Japan Selective Cox-2 Inhibitors Market Size (2014-2019)
• 8.2 Selective Cox-2 Inhibitors Key Players in Japan
• 8.3 Japan Selective Cox-2 Inhibitors Market Size by Type
• 8.4 Japan Selective Cox-2 Inhibitors Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2014-2019)
• 9.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia
• 9.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type
• 9.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application

10 India

• 10.1 India Selective Cox-2 Inhibitors Market Size (2014-2019)
• 10.2 Selective Cox-2 Inhibitors Key Players in India
• 10.3 India Selective Cox-2 Inhibitors Market Size by Type
• 10.4 India Selective Cox-2 Inhibitors Market Size by Application

11 Central & South America

• 11.1 Central & South America Selective Cox-2 Inhibitors Market Size (2014-2019)
• 11.2 Selective Cox-2 Inhibitors Key Players in Central & South America
• 11.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type
• 11.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application

12 International Players Profiles

• 12.1 Boehringer-Ingelheim
  • 12.1.1 Boehringer-Ingelheim Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Selective Cox-2 Inhibitors Introduction
  • 12.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.1.5 Boehringer-Ingelheim Recent Development
• 12.2 TerSera Therapeutics
  • 12.2.1 TerSera Therapeutics Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Selective Cox-2 Inhibitors Introduction
  • 12.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.2.5 TerSera Therapeutics Recent Development
• 12.3 Iroko Pharmaceuticals
  • 12.3.1 Iroko Pharmaceuticals Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Selective Cox-2 Inhibitors Introduction
  • 12.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.3.5 Iroko Pharmaceuticals Recent Development
• 12.4 Apotex
  • 12.4.1 Apotex Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Selective Cox-2 Inhibitors Introduction
  • 12.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.4.5 Apotex Recent Development
• 12.5 Yung Shin Pharmaceutical
  • 12.5.1 Yung Shin Pharmaceutical Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Selective Cox-2 Inhibitors Introduction
  • 12.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.5.5 Yung Shin Pharmaceutical Recent Development
• 12.6 Breckenridge Pharmaceutical
  • 12.6.1 Breckenridge Pharmaceutical Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Selective Cox-2 Inhibitors Introduction
  • 12.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.6.5 Breckenridge Pharmaceutical Recent Development
• 12.7 Meda Pharmaceuticals
  • 12.7.1 Meda Pharmaceuticals Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Selective Cox-2 Inhibitors Introduction
  • 12.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.7.5 Meda Pharmaceuticals Recent Development
• 12.8 Cipla
  • 12.8.1 Cipla Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Selective Cox-2 Inhibitors Introduction
  • 12.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.8.5 Cipla Recent Development
• 12.9 Glenmark Pharmaceuticals
  • 12.9.1 Glenmark Pharmaceuticals Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Selective Cox-2 Inhibitors Introduction
  • 12.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.9.5 Glenmark Pharmaceuticals Recent Development
• 12.10 Teva
  • 12.10.1 Teva Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Selective Cox-2 Inhibitors Introduction
  • 12.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
  • 12.10.5 Teva Recent Development
• 12.11 PuraCap Pharmaceutical
• 12.12 Almirall Limited
• 12.13 Lupin Pharmaceuticals
• 12.14 Aurobindo Pharma
• 12.15 Pfizer
• 12.16 Mylan
• 12.17 Shire Pharmaceuticals
• 12.18 Bayer
• 12.19 Novacap
• 12.20 Abbott
• 12.21 Geri-Care
• 12.22 Perrigo
• 12.23 Kopran
• 12.24 Merck
• 12.25 Hengrui pharmaceutical
• 12.26 Kelun Group
• 12.27 Qilu Pharmaceutical
• 12.28 Taro Pharmaceuticals

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer